Finafloxacin

Finafloxacin
Clinical data
Trade namesXtoro
Routes of
administration		otic, oral, intavenous
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Elimination half-life10 hours
Identifiers
  • 8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H19FN4O4
Molar mass398.394 g·mol−1
3D model (JSmol)
  • O=C(O)C1=CN(C2CC2)c3c(C1=O)cc(F)c(c3C#N)N4C[C@H]5[C@H](C4)NCCO5
  • InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
  • Key:FYMHQCNFKNMJAV-HOTGVXAUSA-N

Finafloxacin (Xtoro) is a fluoroquinolone antibiotic. In the United States, it is approved by the Food and Drug Administration to treat acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.[2]

  1. ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
  2. ^ "FDA approves Xtoro to treat swimmer's ear". Food and Drug Administration. December 17, 2014.